NF-LIGHT®: Ultra-Sensitive NFL Assay for Neurology Research
NF-LIGHT®, our Nfl assay, is an immunoassay kit for the ultra-sensitive measurement of neurofilament light levels in serum, plasma and…
Posted on
Annals Of Neurology | August 16, 2020
Rajan KB, Aggarwal NT, McAninch EA, Weuve J, Barnes LL, Wilson RS, DeCarli CF and Evans DA.
Ann Neurol. 2020 Aug 16
DOI: 10.1002/ana.25874
The longitudinal association of blood biomarkers of total tau (t‐tau), neurofilament light (Nf‐L), and glial fibrillary acidic protein (GFAP) with common sporadic AD and cognitive decline are not established.
Using a single molecule array technology, ultrasensitive immunoassays for serum concentrations of total tau (t‐tau), neurofilament light (Nf‐L), and glial fibrillary acidic protein (GFAP) were measured in a population sample of 1,327 participants (60% African Americans and women) who had a clinical evaluation for AD, completed in‐home cognitive assessments, and undergone 1.5T structural MRI.
Higher concentrations of serum biomarkers were associated with the development of clinical AD, especially, the time‐specific associations were notable: t‐tau 8–16 years, and Nf‐L and GFAP 4–8 years prior to clinical AD. Serum biomarkers were associated with faster cognitive decline over 16 years: baseline t‐tau above 0.40 pg/mL had 30% faster decline, Nf‐L above 25.5 pg/mL had 110% faster decline, and GFAP above 232 pg/mL had 130% faster decline compared to those in the lowest quartile. Participants with baseline GFAP above 232 pg/mL showed 160% faster decline in hippocampal volume compared to those below 160 pg/mL. Additionally, higher baseline t‐tau was associated with faster increase in third ventricular volume, and baseline Nf‐L and GFAP were associated with faster decline in cortical thickness.
Serum t‐tau, Nf‐L, and GFAP predict the development of sporadic AD and cognitive decline, and changes in structural brain characteristics, suggesting their usefulness not only as screening and predictive biomarkers, but also in capturing the pathogenesis of Alzheimer’s dementia.
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
NF-LIGHT®, our Nfl assay, is an immunoassay kit for the ultra-sensitive measurement of neurofilament light levels in serum, plasma and…
Our SIMOA® Tau Kit is designed for the measurement of Tau in serum, human plasma and CSF. Click here to…
Our GFAP assay kit provides ultra-sensitive detection of Glial Fibrillary Acidic Protein in plasma and CSF for neurology research. Click…